{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:08Z","timestamp":1787009048748,"version":"build-2736575974"},"reference-count":116,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune connective tissue disorders are a significant health concern throughout the world with an estimated prevalence of 3% to 5%. They are associated with a variety of autoantibodies that play roles in their diagnosis, risk stratification, prognostication, and\/or management. While some autoantibodies have been well-characterized for use in clinical laboratories, many more are in the research stage. Rapid transition from research to clinical practice, lack of clinical guidelines, and harmonization across a rapidly growing number of commercially available tests create numerous challenges to clinicians and laboratories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>This article briefly discusses common connective tissue disorders and their association with well-known autoantibodies, describes current methods used in clinical laboratories, and outlines their advantages and limitations in the context of these diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Understanding the role of specific autoantibodies and various methodologies for autoantibody testing are important for laboratory professionals who may be introducing\/repatriating new tests, updating existing tests, or advising clinicians\/patients about testing options\/results. Collaboration between laboratory professional staff and clinicians, around the advantages and limitations of each methodology, is also important in their appropriate clinical utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfab131","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T18:35:02Z","timestamp":1634063702000},"page":"114-136","source":"Crossref","is-referenced-by-count":1,"title":["Autoantibodies in Common Connective Tissue Diseases: A Primer for Laboratory Professionals"],"prefix":"10.1093","volume":"7","author":[{"given":"Janet","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Petryayeva","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waliul I","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2022010916492399600_jfab131-B1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/GIM.0b013e3181e074f0","article-title":"Hereditary disorders of connective tissue: a guide to the emerging differential diagnosis","volume":"12","author":"Murphy-Ryan","year":"2010","journal-title":"Genet Med"},{"key":"2022010916492399600_jfab131-B2","doi-asserted-by":"crossref","first-page":"101462","DOI":"10.1016\/j.berh.2019.101462","article-title":"Autoantibodies in connective tissue disease","volume":"34","author":"Mulhearn","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022010916492399600_jfab131-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.03.007","article-title":"Sarcoma-the standard-bearer in cancer discovery","volume":"126","author":"Potter","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022010916492399600_jfab131-B4","doi-asserted-by":"crossref","first-page":"175.12","DOI":"10.4049\/jimmunol.200.Supp.175.12","article-title":"Disruption of self-tolerance in autoimmune diseases and therapeutic modulation to restore immune balance","volume":"200","author":"Chakraborty","year":"2018","journal-title":"J Immunol"},{"key":"2022010916492399600_jfab131-B5","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"2022010916492399600_jfab131-B6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"2022010916492399600_jfab131-B8","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/030097402760375124","article-title":"Hematological manifestations of rheumatoid arthritis","volume":"31","author":"Bowman","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"2022010916492399600_jfab131-B10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MOH.0b013e32834760fb","article-title":"Jr. The spectrum of large granular lymphocyte leukemia and Felty's syndrome","volume":"18","author":"Liu","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"2022010916492399600_jfab131-B13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/qjmed\/hcp165","article-title":"Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies","volume":"103","author":"Song","year":"2010","journal-title":"QJM"},{"key":"2022010916492399600_jfab131-B14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.55563\/clinexprheumatol\/4bcmdb","article-title":"Rheumatoid arthritis autoantibodies and their association with age and sex","volume":"39","author":"Pertsinidou","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2022010916492399600_jfab131-B15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/ard.2005.035691","article-title":"Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis","volume":"64","author":"Nell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2022010916492399600_jfab131-B17","doi-asserted-by":"crossref","first-page":"12068","DOI":"10.1038\/s41598-019-48176-3","article-title":"Citrullination facilitates cross-reactivity of rheumatoid factor with non-IgG1 Fc epitopes in rheumatoid arthritis","volume":"9","author":"Trela","year":"2019","journal-title":"Sci Rep"},{"key":"2022010916492399600_jfab131-B18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10067-020-05412-w","article-title":"Comparison of the analytical and clinical performances of four anti-cyclic citrullinated peptide antibody assays for diagnosing rheumatoid arthritis","volume":"40","author":"Cho","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022010916492399600_jfab131-B19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.170007","article-title":"Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US national observational study","volume":"45","author":"Harrold","year":"2018","journal-title":"J Rheumatol"},{"key":"2022010916492399600_jfab131-B22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the rising study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022010916492399600_jfab131-B23","doi-asserted-by":"crossref","first-page":"19263","DOI":"10.1038\/s41598-020-73919-y","article-title":"Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies","volume":"10","author":"Rodriguez-Mart\u00ednez","year":"2020","journal-title":"Sci Rep"},{"key":"2022010916492399600_jfab131-B24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","article-title":"Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis","volume":"59","author":"de Brito Rocha","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2022010916492399600_jfab131-B25","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.40562","article-title":"Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals","volume":"70","author":"Verheul","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B26","doi-asserted-by":"crossref","first-page":"1759720X21989868","DOI":"10.1177\/1759720X21989868","article-title":"The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA\/RF negative rheumatoid arthritis patients","volume":"13","author":"Kolarz","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022010916492399600_jfab131-B27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-73303-2_3","volume-title":"Outcome measures and metrics in systemic lupus erythematosus.","author":"Johnson","year":"2021"},{"key":"2022010916492399600_jfab131-B29","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2015.00475","article-title":"Mechanisms of kidney injury in lupus nephritis - the role of anti-dsDNA antibodies","volume":"6","author":"Yung","year":"2015","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B32","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1002\/art.27700","article-title":"Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease","volume":"62","author":"Sato","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier","year":"2018","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2022010916492399600_jfab131-B36","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/art.1780361114","article-title":"Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A\/Ro and to SS-B\/La","volume":"36","author":"Julkunen","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.autrev.2008.06.005","article-title":"Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value","volume":"7","author":"Gomez-Puerta","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2022010916492399600_jfab131-B38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00296-018-4059-4","article-title":"The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease","volume":"38","author":"Dima","year":"2018","journal-title":"Rheumatol Int"},{"key":"2022010916492399600_jfab131-B39","first-page":"321359","article-title":"Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects","volume":"2014","author":"Cozzani","year":"2014","journal-title":"Autoimmune Dis"},{"key":"2022010916492399600_jfab131-B40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clindermatol.2003.12.023","article-title":"Drug-induced lupus erythematosus","volume":"22","author":"Antonov","year":"2004","journal-title":"Clin Dermatol"},{"key":"2022010916492399600_jfab131-B41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2011.11.005","article-title":"Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis","volume":"39","author":"Selmi","year":"2012","journal-title":"J Autoimmun"},{"key":"2022010916492399600_jfab131-B42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/08916939709009547","article-title":"Primary biliary cirrhosis an epithelitis: evidence of abnormal salivary gland immunohistochemistry","volume":"26","author":"Tsuneyama","year":"1997","journal-title":"Autoimmunity"},{"key":"2022010916492399600_jfab131-B43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-60327-957-4_17","article-title":"Extraglandular manifestations of Sj\u00f6gren\u2019s syndrome (SS): Dermatologic, arthritic, endocrine, pulmonary, cardiovascular, gastroenterology, renal, urology, and gynecologic manifestations","author":"Fox","year":"2011","journal-title":"Sj\u00f6gren\u2019s Syndrome"},{"key":"2022010916492399600_jfab131-B44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/genes12030365","article-title":"Ophthalmologic manifestations of primary Sjogren's syndrome","volume":"12","author":"Roszkowska","year":"2021","journal-title":"Genes"},{"key":"2022010916492399600_jfab131-B45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren's syndrome as a multi-organ disease: Impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916492399600_jfab131-B46","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/acr.21887","article-title":"Risk of non-Hodgkin's lymphoma in primary Sjogren's syndrome: A population-based study","volume":"65","author":"Johnsen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022010916492399600_jfab131-B47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2022010916492399600_jfab131-B49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.autrev.2010.09.001","article-title":"The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome","volume":"10","author":"Hernandez-Molina","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2022010916492399600_jfab131-B50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B51","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sjogren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/03009740802366043","article-title":"IgA rheumatoid factor in primary Sjogren's syndrome","volume":"38","author":"Peen","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"2022010916492399600_jfab131-B53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2005.12.004","article-title":"Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases","volume":"35","author":"Ramos-Casals","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022010916492399600_jfab131-B55","first-page":"361","article-title":"Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutanious calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia","volume":"114","author":"Winterbauer","year":"1964","journal-title":"Bull Johns Hopkins Hosp"},{"key":"2022010916492399600_jfab131-B56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.33590\/emjrheumatol\/20-00073","article-title":"Systemic sclerosis","volume":"2020","author":"Hughes","year":"2020","journal-title":"EMJ Rheumatol"},{"key":"2022010916492399600_jfab131-B57","first-page":"iii32","article-title":"Renal complications and scleroderma renal crisis","volume":"48(suppl 3","author":"Denton","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916492399600_jfab131-B58","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B59","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B60","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"2022010916492399600_jfab131-B61","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B63","doi-asserted-by":"crossref","first-page":"9692030","DOI":"10.1155\/2020\/9692030","article-title":"Clinical and immunological profile of mixed connective tissue disease and a comparison of four diagnostic criteria","volume":"2020","author":"John","year":"2020","journal-title":"Int J Rheumatol"},{"key":"2022010916492399600_jfab131-B64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/keh024","article-title":"Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker","volume":"43","author":"Simon","year":"2003","journal-title":"Rheumatology"},{"key":"2022010916492399600_jfab131-B65","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B66","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"2022010916492399600_jfab131-B67","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"2022010916492399600_jfab131-B68","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2022010916492399600_jfab131-B69","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"2022010916492399600_jfab131-B70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2022010916492399600_jfab131-B71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1759720X11415306","article-title":"Diagnosis and treatment of the idiopathic inflammatory myopathies","volume":"3","author":"Gazeley","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022010916492399600_jfab131-B72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"2022010916492399600_jfab131-B73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"2022010916492399600_jfab131-B74","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andras","year":"2008","journal-title":"J Rheumatol"},{"key":"2022010916492399600_jfab131-B75","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B76","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B77","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/BOR.0000000000000549","article-title":"Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies","volume":"30","author":"Oldroyd","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2022010916492399600_jfab131-B78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2022010916492399600_jfab131-B79","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/1756-185X.13559","article-title":"Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry","volume":"22","author":"Nuno-Nuno","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2022010916492399600_jfab131-B80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00296-020-04779-y","article-title":"Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the myocite cohort","volume":"41","author":"Naveen","year":"2021","journal-title":"Rheumatol Int"},{"key":"2022010916492399600_jfab131-B81","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: a new classification of adult autoimmune myositis","volume":"69","author":"Senecal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B82","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2022010916492399600_jfab131-B83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022010916492399600_jfab131-B84","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2022010916492399600_jfab131-B85","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","article-title":"Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916492399600_jfab131-B86","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2022010916492399600_jfab131-B87","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-Pl7 and anti-Pl12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916492399600_jfab131-B88","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"2022010916492399600_jfab131-B89","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"2022010916492399600_jfab131-B90","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"2022010916492399600_jfab131-B91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B92","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217166","article-title":"Terminology and definition of \u2018antinuclear antibodies\u2019: history and current debate","author":"Markewitz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B93","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/annrheumdis-2019-215610","article-title":"Response to: \u201cThe utility of the HEp-2000 antinuclear antibody substrate","volume":"79","author":"Damoiseaux","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B94","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2019-215519","article-title":"Utility of the HEp-2000 antinuclear antibody substrate","volume":"79","author":"Lee","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010916492399600_jfab131-B95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13317-020-00139-9","article-title":"Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey","volume":"11","author":"Van Hoovels","year":"2020","journal-title":"Auto Immun Highlights"},{"key":"2022010916492399600_jfab131-B96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12098-015-1936-7","article-title":"Autoantibodies and their judicious use in pediatric rheumatology practice","volume":"83","author":"Saikia","year":"2016","journal-title":"Indian J Pediatr"},{"key":"2022010916492399600_jfab131-B97","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","article-title":"Range of antinuclear antibodies in \u201chealthy\u201d individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B98","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2020-0094","article-title":"A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases","volume":"59","author":"Orme","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"2022010916492399600_jfab131-B99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1373\/jalm.2016.020172","article-title":"Utility of antinuclear antibody screening by various methods in a clinical laboratory patient cohort","volume":"1","author":"Deng","year":"2016","journal-title":"J Appl Lab Med"},{"key":"2022010916492399600_jfab131-B100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"2022010916492399600_jfab131-B101","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"Hov","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2022010916492399600_jfab131-B102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/antib10010009","article-title":"Antinuclear autoantibodies in health: Autoimmunity is not a synonym of autoimmune disease","volume":"10","author":"Pashnina","year":"2021","journal-title":"Antibodies"},{"key":"2022010916492399600_jfab131-B103","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/art.30084","article-title":"Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases","volume":"63","author":"Mariz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1744666X.2019.1562903","article-title":"Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness","volume":"15","author":"Mahler","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2022010916492399600_jfab131-B105","doi-asserted-by":"crossref","first-page":"102637","DOI":"10.1016\/j.autrev.2020.102637","article-title":"Monospecific anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fine speckled pattern\u2014a systematic review and meta-analysis of diagnostic test accuracy","volume":"19","author":"Cheng","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022010916492399600_jfab131-B106","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing\u2014misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2022010916492399600_jfab131-B107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jcla.1860030108","article-title":"Microplate ELISA for detection of antibodies to DNA in patients with systemic lupus erythematosus: specificity and correlation with Farr radioimmunoassay","volume":"3","author":"Sutjita","year":"1989","journal-title":"J Clin Lab Anal"},{"key":"2022010916492399600_jfab131-B108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10067-017-3771-x","article-title":"The performance of different anti-dsDNA autoantibodies assays in Chinese systemic lupus erythematosus patients","volume":"37","author":"Zhao","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022010916492399600_jfab131-B109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41927-020-00132-9","article-title":"Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results","volume":"4","author":"To","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2022010916492399600_jfab131-B110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.41088","article-title":"Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun research line blot","volume":"72","author":"Mecoli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B111","doi-asserted-by":"crossref","first-page":"1759720X20975907","DOI":"10.1177\/1759720X20975907","article-title":"The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study","volume":"12","author":"Lackner","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022010916492399600_jfab131-B112","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology"},{"key":"2022010916492399600_jfab131-B113","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022010916492399600_jfab131-B114","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.41228","article-title":"Clinical significance of higher cutoffs for myositis autoantibody positivity using the Euroimmun research line blot: Comment on the article by mecoli et al","volume":"72","author":"Zampeli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492399600_jfab131-B115","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00415-019-09266-4","article-title":"Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study","volume":"266","author":"Montagnese","year":"2019","journal-title":"J Neurol"},{"key":"2022010916492399600_jfab131-B116","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front Immunol"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/114\/42084049\/jfab131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/114\/42084049\/jfab131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T20:28:14Z","timestamp":1699648094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/7\/1\/114\/6498247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab131","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}